Myovant Sciences Ltd. (NYSE:MYOV) Insider Sells $174,322.98 in Stock

Myovant Sciences Ltd. (NYSE:MYOVGet Rating) insider Uneek Mehra sold 9,243 shares of Myovant Sciences stock in a transaction on Friday, September 16th. The shares were sold at an average price of $18.86, for a total transaction of $174,322.98. Following the completion of the sale, the insider now directly owns 204,937 shares of the company’s stock, valued at approximately $3,865,111.82. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Myovant Sciences Price Performance

Myovant Sciences stock opened at $17.43 on Friday. The firm has a fifty day moving average price of $16.35 and a two-hundred day moving average price of $13.31. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -9.90 and a beta of 2.28. Myovant Sciences Ltd. has a fifty-two week low of $7.67 and a fifty-two week high of $24.96.

Myovant Sciences (NYSE:MYOVGet Rating) last released its earnings results on Wednesday, July 27th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.09). The company had revenue of $116.49 million for the quarter, compared to analyst estimates of $107.30 million. As a group, sell-side analysts expect that Myovant Sciences Ltd. will post -1.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MYOV. The Goldman Sachs Group boosted their target price on shares of Myovant Sciences from $9.00 to $10.00 and gave the stock a “neutral” rating in a research report on Thursday, July 28th. SVB Leerink raised shares of Myovant Sciences from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $23.00 in a research report on Tuesday, August 9th.

Institutional Investors Weigh In On Myovant Sciences

Several hedge funds have recently made changes to their positions in MYOV. State Street Corp lifted its stake in shares of Myovant Sciences by 16.2% in the first quarter. State Street Corp now owns 3,334,935 shares of the company’s stock valued at $44,421,000 after buying an additional 464,627 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Myovant Sciences by 98.7% in the second quarter. Goldman Sachs Group Inc. now owns 418,336 shares of the company’s stock valued at $5,200,000 after buying an additional 207,827 shares during the period. Millennium Management LLC lifted its stake in shares of Myovant Sciences by 314.5% in the second quarter. Millennium Management LLC now owns 265,388 shares of the company’s stock valued at $3,299,000 after buying an additional 201,362 shares during the period. JPMorgan Chase & Co. lifted its stake in Myovant Sciences by 576.3% during the second quarter. JPMorgan Chase & Co. now owns 234,391 shares of the company’s stock worth $2,913,000 after purchasing an additional 199,733 shares during the period. Finally, Bank of America Corp DE lifted its stake in Myovant Sciences by 1,405.2% during the fourth quarter. Bank of America Corp DE now owns 153,953 shares of the company’s stock worth $2,398,000 after purchasing an additional 143,725 shares during the period. Institutional investors own 30.62% of the company’s stock.

Myovant Sciences Company Profile

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Articles

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.